MDR1 gene therapy - Genetic Therapy

Drug Profile

MDR1 gene therapy - Genetic Therapy

Latest Information Update: 21 Mar 2007

Price : $50

At a glance

  • Originator Genetic Therapy
  • Class Chemoprotectants; Gene therapies
  • Mechanism of Action Gene transference; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chemoprotection

Most Recent Events

  • 19 Jun 2001 This gene therapy product is in active development
  • 17 Feb 1997 Phase-I clinical trials for Chemotherapy induced damage (Prevention)/Chemoprotection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top